Medtronic PLC vs Zscaler Inc — how do they compare? Medtronic PLC trades at $82.45 (market cap $106.61B), while Zscaler Inc trades at $148.33 (market cap $24.23B). The key difference: Medtronic PLC is far larger — about 4.4× Zscaler Inc's market cap, and Medtronic PLC pays a 3.46% dividend while Zscaler Inc pays none. Which is the better fit depends on your goals.
| MDT | ZS | |
|---|---|---|
Market Cap | $106.61B | $24.23B |
Sector | Health | Technology |
52-Week High | $105.35 | $336.27 |
52-Week Low | $73.75 | $118.05 |
Enterprise Value | $125.36B | $22.55B |
Dividend Yield | 3.46% | — |
Signals from Pluang's Aura AI — not financial advice
Medtronic (MDT) trades at $83.54, up 0.41% today, with a bullish technical signal from moving averages. The company reported strong revenue growth to $33.54B in 2025 and has beaten EPS estimates for three consecutive quarters. Recent acquisitions, including SPR and Scientia Vascular, expand its pain therapy and neurovascular portfolios. Valuation ratios show a P/E of 22.31 and P/S of 2.95, with a consensus price target of $97.50 implying significant upside.
The outlook is positive, supported by robust fundamentals, analyst optimism, and strategic expansions. Key risks include rising debt levels and competitive pressures in medical technology. With no sell ratings from analysts and a dividend yield near a decade high, MDT presents a compelling long-term opportunity for growth and income investors, though macroeconomic and execution risks warrant monitoring.
Zscaler (ZS) trades at $150.70, up 0.54% with a bullish technical outlook. The stock shows strong revenue growth from $1.1B in 2022 to $2.67B in 2025, though remains unprofitable with a -2.44% net margin. Recent earnings consistently beat expectations, and analyst consensus is strongly bullish with a $192.46 price target. However, the company faces class action investigations and rising AI infrastructure costs that pressure margins.
ZS presents a growth opportunity in cybersecurity with Zero Trust adoption and AI security traction, but investors must weigh persistent losses against high valuation multiples. The stock's 34% YTD decline creates potential upside if execution improves, though competitive pressures and profitability concerns remain key risks.
Trailing returns across standard periods
Latest headlines on both assets
One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →Zscaler is a security-as-a-service firm that offers its customers cloud-delivered solutions for protecting user devices and data. The firm leverages its position in 150 colocation data centers to deliver traditionally appliance-based security functionality, such as firewalls and sandboxes, as a completely cloud-native platform. The firm focuses on large enterprise customers and offers two primary product suites: Zscaler Internet Access, which securely connects users to externally managed application and websites (such as Salesforce and Google), and Zscaler Private Access, which securely connects users to internally managed applications. Both product suites encompass a broad gamut of capabilities situated across the traditional security stack.
Read more on ZS →